CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3
This study, called CABONEN, is looking into a medicine called cabozantinib for patients who have an advanced, specific type of neuroendocrine cancer (G3). Neuroendocrine cancers start in special cells throughout the body. This trial aims to find out how effective cabozantinib is at controlling the cancer's growth over time. Researchers will be checking if the cancer shrinks, stays the same, or grows slower after treatment. They will also look at how patients feel and their overall quality of life while taking the medicine. This is a "Phase II" study, which means it's an important step to see if this treatment works well enough to be tested in larger studies later on.
At a glance
What is this study about?
This research study, named CABONEN, is exploring the effects of a drug called cabozantinib in people who have an advanced form of neuroendocrine cancer, specifically a type described as 'G3' (which means it's a faster-growing kind). Neuroendocrine cancers are a group of unusual cancers that develop from neuroendocrine cells, which are found all over the body. The main goal of this study is to see how well cabozantinib can control the cancer. This means checking if the cancer shrinks, stops growing, or grows at a much slower rate over six months.
Researchers will also be looking at several other important things. They will check the cancer's response at different times, like after three months and a full year. They will also see how long people live without their cancer getting worse, and how long they live overall. An important part of the study is understanding how the treatment affects patients' everyday lives. Therefore, participants will regularly fill out special questionnaires about their quality of life.
By carefully studying these different aspects, doctors hope to learn if cabozantinib could be a helpful treatment option for people with this specific type of advanced neuroendocrine cancer. The information gathered from this "Phase II" study will help decide if this drug should be investigated further in even larger studies.
Key takeaways
- This study tests a new drug, cabozantinib, for advanced neuroendocrine cancer.
- It aims to see how well the drug controls cancer growth and affects quality of life.
- Participation involves taking tablets, regular check-ups, and filling out health surveys.
- It's a 'Phase II' study, an important step in testing new treatments.
- You can stop participating at any time if you change your mind.
Who may be eligible?
To join this study, you must be at least 18 years old. Both men and women are welcome to participate. The study is specifically for people who have been diagnosed with advanced neuroendocrine cancer, which means the cancer has spread or cannot be removed by surgery.
More detailed medical checks will be done by the study team to make sure it's safe and appropriate for you to join. These checks will ensure that the treatment being tested is suitable for your specific health situation and type of cancer.
It's important to discuss your health history with the study doctors so they can determine if this study is the right fit for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with advanced neuroendocrine cancer (G3 type)?
- Are you willing to take study tablets and attend regular appointments?
- Are you comfortable filling out questionnaires about your health and feelings?
What does participation involve?
If you decide to take part in this study, you would be given cabozantinib tablets to take. These come in different strengths, and the study team will guide you on the correct dose. You would have regular appointments, likely including physical check-ups, blood tests, and scans to monitor your cancer and overall health. You would also be asked to complete questionnaires about your quality of life every month for the first year, and then again after 15 months.
The study will carefully track any side effects you experience. A special safety board will also closely watch all participants to ensure their safety. The total duration of your participation, including follow-up, will be decided by the study doctors, but monitoring of your condition and safety is ongoing.
Potential risks and benefits
Locations (2)
- —UnverifiedAustria
- —UnverifiedGermany
Common questions
What is 'advanced' neuroendocrine cancer?
Advanced cancer means the cancer has either spread to other parts of the body or cannot be completely removed by surgery.
What does a 'Phase II' study mean?
A Phase II study means researchers are testing a new treatment in a small group of people to see if it works and is safe enough to be tested more widely.
What is cabozantinib?
Cabozantinib is a medicine that aims to stop cancer cells from growing and spreading by targeting specific pathways that help the cancer survive.
What does 'disease control rate' mean?
Disease control rate means how many people in the study have their cancer shrink, stay the same, or grow slower after treatment. It's a way of measuring if the medicine is having a positive effect.
Will this study cure my cancer?
This study is testing a new treatment and aims to control the cancer's growth and improve quality of life, but it cannot promise a cure.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.